Y Intercept Hong Kong Ltd Trims Position in Liquidia Corporation $LQDA

Y Intercept Hong Kong Ltd trimmed its position in Liquidia Corporation (NASDAQ:LQDA) by 58.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,583 shares of the company’s stock after selling 36,652 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Liquidia were worth $582,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Tyro Capital Management LLC purchased a new position in shares of Liquidia during the 2nd quarter worth $15,473,000. CenterBook Partners LP lifted its position in Liquidia by 811.7% in the second quarter. CenterBook Partners LP now owns 1,103,850 shares of the company’s stock valued at $13,754,000 after buying an additional 982,778 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Liquidia by 157.2% during the second quarter. BNP Paribas Financial Markets now owns 482,822 shares of the company’s stock worth $6,016,000 after buying an additional 295,104 shares during the period. Marshall Wace LLP increased its position in shares of Liquidia by 58.6% during the second quarter. Marshall Wace LLP now owns 660,762 shares of the company’s stock valued at $8,233,000 after acquiring an additional 244,235 shares during the last quarter. Finally, Opaleye Management Inc. raised its stake in shares of Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after acquiring an additional 215,000 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LQDA shares. HC Wainwright lifted their target price on shares of Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. Jefferies Financial Group increased their target price on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Raymond James Financial restated a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a report on Tuesday, November 4th. Finally, Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Liquidia Trading Up 5.5%

NASDAQ:LQDA opened at $46.63 on Wednesday. The stock has a 50-day simple moving average of $36.02 and a 200-day simple moving average of $28.52. The stock has a market cap of $4.06 billion, a P/E ratio of -32.38, a P/E/G ratio of 1.24 and a beta of 0.46. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $46.67. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm’s revenue for the quarter was up 1106.7% on a year-over-year basis. As a group, analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the completion of the sale, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 21,142 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the transaction, the insider directly owned 176,883 shares in the company, valued at approximately $6,620,730.69. The trade was a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 252,476 shares of company stock valued at $9,173,435. 30.10% of the stock is owned by insiders.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).